CytoSorbents gets CytoSorb EU approval for removal of ticagrelor during CPB
CytoSorbents has secured approval from the European Union (EU) for its CytoSorb extracorporeal blood purification therapy for the removal of anti-platelet agent ticagrelor during surgery requiring cardiopulmonary bypass (CPB). The CytoSorb whole blood adsorber has also been given CE Mark label expansion for the indication. It was earlier approved in the European Union for the […]
AstraZeneca has signed a deal valued at about $390 million with Atnahs Pharma, a portfolio company of Triton Fund V, to sell five of its hypertension drugs to the latter as they have lost patent protection across the world. The deal will give Atnahs Pharma the global commercial rights to the hypertension medicines – Inderal (propranolol), […]
Continue reading …
Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in separate agreements, as per the latest pharma acquisition news. Financial details of the two deals have not been disclosed. The divestments are being taken up in an effort to wrap up the $63 billion AbbVie acquisition of […]
Continue reading …AstraZeneca taps into Gatehouse Bio’s sRNAlytics AI platform for drug discovery
December 5, 2019 No Comment
US biodata company Gatehouse Bio is joining forces with pharma giant AstraZeneca to accelerate the discovery of new drugs for respiratory and cardiovascular diseases using sRNAlytics, the former’s artificial intelligence (AI)-driven platform. According to Gatehouse Bio, the sRNAlytics platform is capable of identifying new small RNA (sRNA) signatures and can illuminate molecular pathways correlated to […]
Continue reading …
AstraZeneca has bagged approval from the US Food and Drug Administration (FDA) for the self-administration of FASENRA (benralizumab) through FASENRA Pen, a pre-filled, single-use auto-injector, for the add-on maintenance treatment of severe asthma in patients aged 12 years and older, and with an eosinophilic phenotype. FASENRA is a monoclonal antibody which directly binds to the […]
Continue reading …PAOLA 1 trial results : Lynparza, bevacizumab combo achieves PFS goal in phase 3 trial
August 15, 2019 No Comment
PAOLA 1 trial results : Lynparza (olaparib), a cancer drug which was jointly developed by AstraZeneca and MSD, in combination with bevacizumab, met the primary endpoint of the phase 3 PAOLA 1 clinical trial in patients with advanced ovarian cancer. The PAOLA 1 primary endpoint is the statistically-significant and clinically-meaningful improvement shown by Lynparza plus […]
Continue reading …Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS
August 11, 2019 No Comment
Tagrisso FLAURA trial results : Pharma giant AstraZeneca said that the phase 3 FLAURA trial evaluating Tagrisso (osimertinib) in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) has yielded positive overall survival (OS) results. The randomized, double-blinded, multicenter late-stage trial featured NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) […]
Continue reading …
Verdiperstat phase 3 MSA clinical trial : US biopharma company Biohaven Pharmaceutical has enrolled the first patient in a phase 3 clinical trial to assess the efficacy and safety of verdiperstat (formerly known as AZD3241) in patients with Multiple System Atrophy (MSA), a rare neurodegenerative disorder. Licensed from AstraZeneca in September 2018, verdiperstat is an […]
Continue reading …
Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency’s (EMA) approval for their poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) to be used for the treatment of a type of advanced breast cancer. The expanded Lynparza EMA approval allows the PARP inhibitor to be used as […]
Continue reading …FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia treatment
September 14, 2018 No Comment
Lumoxiti FDA approval : AstraZeneca has bagged the US Food and Drug Administration (FDA) approval for its CD22-directed cytotoxin Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of relapsed or refractory hairy cell leukaemia (HCL). Lumoxiti FDA approval for hairy cell leukaemia treatment is for adult patients who had undergone more than two systemic therapies in the […]
Continue reading …
Business News Today
- Marqeta raises $150m for card issuing platform, takes valuation to $4.3bn
- Monument Re wraps up acquisition of Bermuda-based GreyCastle
- COVID-19 forces Texas Capital, Independent Bank to call off $5.5bn merger
- Genstar wraps up sale of Innovative Aftermarket Systems to iA Financial
- Cleareye.ai acquires Indian artificial intelligence company AIWare.ai
- Fresh Del Monte Produce begins operations at fresh cut plant in Yokohama
- Carlsberg, Marston’s to create Carlsberg Marston’s Brewing Company in UK
- FRP wraps up Carluccio’s sale to Boparan Restaurant Group
- GE to provide turbines for POWERICA’s Rajkot and Khambaliya wind farms
- KKR to invest $150m in Reliance’s digital services business Jio Platforms
